Alseres CEO notes molecular-imaging candidate is in Phase III studies

06/12/2008 | PharmaLive.com

Alseres Pharmaceuticals' lead molecular-imaging candidate, Altropane, is in two-part Phase III clinical trials to test its diagnostic efficacy in Parkinson's disease patients with tremor, according to the company chairman and CEO's annual letter to stockholders.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC